When the world goes wary with Information technology, biotechnology is all set to steal the show and doing the rounds as perceived by experts. This issue brings in an insight into the persisting scenario in and around IT and BT. Whether BT can match IT is the heated question right now and whether it can do all the wonders that IT did to India is the most awaited answer. Intriguing the reader throughout, this issue offers you the most debatable and high on the spot issues such as \'Patent wars\' and whether \'Recycling is healing or hurting the environment\'. To interest our readers from core research, \'Nanotechnology..A walk into the future and the \'Changing dynamics of Biosupplier industry does the needful. The drawbacks of the current biotechnology scenario in India is crafted out neatly in \'Where we fell short...In our quest to follow the best\'. Keeping yourself updated about the news and the happenings of the bio-world, March issue has every flavor to offer.

CSIR Raman Research Fellowship 2019-2020 notification is out.

This issue covers the story of a  young vibrant personality who raised to success and fame in the healthcare sector, the space which is largely dominated by the male peers. As she ventured into the entrepreneurial road, she not only grabbed the investor's trust but became media's favourite. Attaining the feat of being a billionaire before turning 30 was after all a no minor feat! But the fairytale rise of Elizabeth Holmes’ Theranos soon came to a horrendous fall. Find out the truth behind its speculated fraud, revoking its California lab license and banning the charming young entrepreneur from the business for at least two years in this issue. 

Other articles to interest are “The DeepMind controversy- is patient data at risk”, article on “AI, Robotics and Biotech” , “Ebola sets for a scathing re-entry”, “Turning waste into wealth” and more.
 
Our utmost gratitude to Mr. Vijay G. Pande, Managing Director, Vijyoti and Mr. R.P Mishra, Director, Innovation LifeSciences for sparing their precious time and interacting with Biotecnika magazine.

The deadly wrath of Zika might soon be at rest and more treatments could be pouring in to cure it and more methods at its way to control its spread. It could be achieved now as the most gruelling task of decoding the entire structure of the virus has been achieved by a group of researchers from Purdue University. 

The issue not only covers how the virus structure was unveiled but also the proud moment of an Indian being the part of this extraordinary finding. 
Ms. Devika Sirohi, a PhD scholar at Purdue, was the youngest member of the team who decoded Zika virus structure. Read the exclusive coverage on this young scientist, the findings of the research and what it could hold in the future. 

Other features included in the issue are “Super 13: the world of X-men and superhumans is here”, “GMO special article: Would losing on GMO take a toll on environment, economies too?”, “Why are billionaires investing if BT has no scope?” and more.
 
Special thanks to Mr. Ketan Zota, Director, Zota Healthcare and Mr. Robert Balderas, VP, Market Development, BD Biosciences, USA who took out precious time from their busy schedule to interact with Biotecnika magazine.

There is no denying in the fact that the ‘women-force’ forms the most substantial and effective workforce, and that they have stood at par with the male counterparts at every levels and at every field. In life science sector too, they have not only busted the popular belief that entrepreneurship is a male dominated area but also proved their prowess beyond exceptional. Celebrating the success and opulence of women in the life science industry, we have picked out 10 such names that made it big in the industry and with much aplomb. However with the ever growing life science and biotech sector, the success stories are not limited to these 10 names but reaches far beyond.
 
Other stories to interest are “Storing Brain to computer- the unrealistic way!” which talks about the idea of being immortal by transferring brain to computer, “Monsanto- India spat and whether it would risk GM prevelance in the country”, “What Budget 2016 has to offer to the life science sector” and much more. Also read the conversation of Biotecnika magazine with Mr. Niven N Narain, CEO and Founder, Berg Heathcare.

The unchecked spread of virus created a situation of panic in major parts of the globe to an extent of a "Global health emergency" being declared by the WHO. "Zika", the miniature devil wrecked the lives of many especially infants who were being born with deformity called "microcephaly". While many linked it to Zika, there were also theories of it being spread by an experimental pesticide by Monsanto which was used in Brazil. Amidst the miseries, controversies, speculations and cures, Zika wrath has surely made an headline and we have covered the various aspects of Zika in this issue. 

More in this edition are the controversy around cultivation of GM mustards,  the affect on Indian exporters of mandate by the US government to manufacture APIs locally, a fun read on body parts that we no longer need  to name a few.

A special thanks to Dr. Shivendra Bajaj, Executive Director, ABLE-AG and to Mr. Amit Chopra, MD ThermoFisher India and Mr. Mark Field, CTO, ThermoFisher who interacted with us.

Being a BT professional in India is often speculated as the path towards struggle and why not- it is often surrounded by questions like will it pay me the best, does it offer enough pay hikes, do I have a job security and many more. But this new year might bring a smile to the BT professionals in India as the salary survey conducted by Mercer’s All Industries Total Remuneration says that it might witness the highest pay rise in the year 2016! Amidst the expectations of an increase in the base salaries of overall industries by 10.5%, life science domain would get lucky in terms of hike. The covers story speaks about the same which makes up for a must read. 

Other stories to interest are start-up scheme by Modi and how it could enhance biotech business in the country,  focusing on the talks of the science connoisseurs in the Indian National Congress held at Mysore which focuses on inventing in India, Samsung embracing biotech business and stepping into the lines of Google and much more.

Special thanks to Dr. Ramesh Raliya, Research Scientist, Nano Research facility, Washington University for interacting with Biotecnika magazine. The issue also covers an interaction with Mr. Ankur Parikh, Director, Industrial UV at Alfaa UV. Also read tete-a-tete with Mr. Mark Field, CTO and Mr. Amit Chopra, MD, ThermoFisher India at the inauguration of New Emerging Digital Technology Centre at Bangalore.

A very happy new year from the entire team of Biotecnika to its readers! While another year unfolds with its blank pages to be filled afresh, we hope for another action packed year. When it comes to biotechnology there were many stories that made headlines, but as the year was trending towards end, what caught everyone’s attention was the biggest fraud committed in the sector in 2015. Quoted as the “biotech biggest fraud” and the man involved in it as the “most hated man” in the entire globe, this new year special issue brings to you a story of success, greed and eventually a lesson that could be learnt from- story of Martin Shkreli and his unrealistic drug price hike and other frauds.
 
Many more stories that promises to keep readers engaged are “Captagon- Captivating ordinary to extraordinary!”, “Environmental chaos and biotech solution”, “Top 10 biotech/healthcare firms backed by Google and much  more. Special thanks to Dr. Maryam Sadeghi, Director, Digital Health Hub at Simon Fraser University and CEO & Founder at MetaOptima Technology Inc and Mr. Samartha Jain, CEO & Founder, Positive Biosciences for their precious time.
 
Grab your New Year special issue now!

Promoting women entrepreneurship, green solutions and development of eco-friendly techniques are on their agenda and are determined to make it a reality very soon! We are talking about the two women entrepreneurs Gayathri Thankachi and Aadra Chandra Mouli, who are currently leading the biotech company Aeka Biochemicals based in Kerala. They are focused on serving the society through Aeka while staying green in all ways.

Aeka manufactures biotechnological, biochemical & enzymatic products, chemical products or extracts of biological origin, and can be applied directly or indirectly in the development of products for relevant uses. In this issue read the story of Gayathri Thankachi and Aadra Chandra Mouli, the women entrepreneurs and founders of Aeka Biochem, who lead the first women owned biotech company. Other stories to grab your interest are Reversing aging, How Theranos, a successful biotech company rose and fell, Antibiotics and if they are nearing an end, Top 10 bioindustry trends for 2016 indicating the most importantly upcoming biotrends for the coming year and many more.

Special thanks to Dr. Amol Raut, CEO, GeneSupport; Shiladitya Sengupta and Ms. Dorothy Lou, Lead Business Development, Transcriptic (US) for their valuable contribution in bringing together their opinions on various verticals of bioindustry.

Grab our copy and be a part of the latest from the biotech industry! Subscribe now!

A successful road taken towards entrepeneurship in itself is a story to be inspired from and when the leader in the picture is a 30 year old Indian biotech entrepreneur, it could afford no miss even by a blink. In this issue read the story on Vivek Ramaswamy, an American based CEO who fetched world's largest IPO in biotech from an outcasted drug by GSK. Other stories to grab your interest are Artificial intelligence and if it has the potential to serve as a fairer option to drug discovery, Biosimilars and if India is competent enough in dealing with it, Top 10 pharma firms of 2015 based on their market capital and many more.

Special thanks to Dr. Geeta Shroff, the brain behind human stem cell line and Mr. Sunil Bhambarkar, President, Gattefosse India for their precious contribution in the making of their story, David Green, International biotech communication expert and Dr. Shivendra Bajaj, Executive Director ABLE AG for throwing an insight on GM technology.

It has been two successful years since Biotecnika magazine has taken stage and after traversing for two years, our ardor to serve the biotech industry has just doubled. With this edition, we celebrate the second anniversary of the magazine by highlighting the dedicated support to the industry, initiatives to promote the sector, looking at flaws for the betterment of the sector and much more. With this in mind, Biotecnika once again covers the topic that needs to be looked upon from a common man’s perspective.

As part of the cover feature, we have Dr. VA Shiva Ayyadurai in an exclusive interview with Biotecnika Magazine. The biotech industry was much appalled when the proclamations by Dr.VA Shiva about the rampant corruption inside the gates of CSIR hit the news-stands. He was in and out of CSIR within 5 months of his hiring, as his report claims of underlying bureaucracy inside the organization, questioning the credibility of CSIR. Listen to Dr Shiva himself as he uncovers the complete story in this issue.

Also, the interest levels reach an acme as we have on board Dr. Sergio Canavero, the first person behind the human head transplant initiative. Do not miss an exclusive feature on Prof. Canavero as the professor interacted with Biotecnika magazine, as part of its second anniversary special issue.
 
While October issue is all about celebrating the second anniversary, we included features in the order of 24 issues-24 milestones, Digital India's impact on healthcare, Is polio staging a comeback?' and our ardent support to GM technology.
 
This anniversary, grab our copy and be a part of the latest from the biotech industry! Subscribe now!

While the government is too keen on implementing DNA Profiling Bill in the upcoming Parliamentary sessions, not everybody seem to be convinced with the much controversial bill, and why not? The Bill raises some serious concerns such as how far is the data secured? Would the DNA bank assure no infringement with the privacy of the data? Are strong regulatory bodies set in place to oversee the Bill and much more? The current issue of Biotecnika magazine covers the complete gist of the DNA Profiling Bill 2015- a must have & read!

Apart from this also read topics to interest the human ingenuity such as Super human genes, Cloud Computing, Top 7 Bioprinting breakthroughs of 2015”, tete-a-tete with Mr. Robert Nass, VP, Quality and Regulatory Management, Merck, coverage of inauguration ceremony of Thermo Fisher’s Technology Development Centre and a lot more! Grab your copy now to keep yourself at par with the industry updates.

Controversies hovering food industry are many, but one recent entry has pushed the industry into a precarious situation. The most favourite breakfast snack, Maggi, was banned by the Indian authorities, post which, people are beginning to doubt every packed food on the grocery store shelf. The issue has triggered a fear and also fury among the loyal bunch of consumers. As Nestle was pointed fingers at, there were also questions raised on the authenticity of the food quality analysis as carried out by the India Quality Control Analysts. Trying to analyse whether the brand was truly a killer or did it just mistakenly land into trouble, forms the background for our August issue cover feature titled, “Maggi: Silent killer brand or silently killed?”
 
Moving along, other features to interest you include CRO market, Top 7 CRO companies in emerging markets, Can GMOs offer solace to environmental crisis, and Surging insulin market. Also featured are the interviews with Dr. Amar Desai, Research associate at Case Western Reserve and also one of the research team members behind ‘Tissue regeneration drug’ and Mr. Ambuj Jain, India General Manager at Cambridge Consultants. Do not miss on what they had to say on the Indian bioresearch and pharma industry. Grab your copy now!

Along with the advent in technology that biotechnology has favoured to mankind, in rare cases there have been findings that could not go down well with people. GMOs are one such overly criticized technology which has received more suspicion than praises. In a false propaganda against GM crops, myths tend to weigh more than truth about it- for which media to a great extend could be blamed. With exponentially increasing population that could soon be followed by a shortage of food worldwide, GM technology could actually prove to be a boon, albeit anti GMO NGOs stop opposing. July cover features the same under the title “It’s time to prosecute anti-GMO NGOs- Combating false propaganda against GMO companies”.
 
Other stories to keep the interest up are “How to start a company in biotech”, “Will you get your genome sequenced- a global picture”, ‘Top 10 employers in biotechnology” and much more. Also featured are the talks with industry stalwart- Mr. Sumit Mitra, Global Marketing Manager, MolBio Diagnostics and Mr. G.S Krishnan, Regional President, Novozymes. What are you waiting for; grab your copy today to get new insights into the industry with Biotecnika magazine!

EditorBiotechnology sector is quite infamously famous for often receiv-ing the new comers into the industry quite coldly. Be it in terms of infrastructure, getting required approvals or even fetching investors, a bio-preneur’s tale has many villains to overcome before they could actually celebrate a success story. The June issue is dedicated to all the start ups in the industry who have tried hard to make a mark and to those who are still in the rising. The cover story revolves around the ‘hide and seek’ between biotech start ups and the investors and how compatible do they stand out compared to other sectors. Though biotech sector stays ambitious in terms of reaching a top spot in the charts but do we have enough opportunities for its people? We talk about the profit, but is there patience to wait for the returns? Quite sadly, no. Investors, who are mostly in a jiffy of looking for short term benefits often neglect on the huge profits that biotech could bring. There are a lot of strategies and improvements which if adopted could drastically change the scenario. Although in bits and pieces, we are heading towards that layout which is supportive of bio-preneur taking its step smoothly into the sector. Give a definite read to this biotech entrepreneur and investor relationship existing in India in the ‘BT start up special’ issue.

The Indian biotech sector faced a major turn of events when Daiichi Sankyo, Japanese firm whose hide and seek with Indian drug company Ranbaxy came to an end as it decided to sell off its entire holding of  Sun Pharmaceutical Industries and exit Indian pharma sector after a struggle of eight years. Why it had to offload Ranbaxy and what is in store with the company’s future businesses, find out in Biotecnika magazine’s May 2015 issue. Other stories to keep reader’s interest intact are “India succumbs to H1N1”, “Are we amid biotech bubble”, “Is it time to kill your R&D project?” and much more. Biotecnika bureau had a chance to interact with Ms. Anu Acharya, CEO, Mapmygenome on her entrepreneurial voyage and Dr. Anurag Mathur, Lead author, “Heart-on-chip” on his recent research. Grab your copy to find out what they had to say!

The surge in technology has made our lives easy in every form and its contribution towards improving healthcare is surely commendable. With an increasing trend in healthcare apps, Apple Inc. has taken a step forward and has brought in a concept of ResearchKit which has nested apps for various diseases such as asthma, cardiovascular ailments, Parkinson and much more. It allows its users to conduct tests and take part in studies hence claiming to revolutionize the way data is generated for clinical studies. Will Apple ResearchKit be a big hit? Read Biotecnika April issue to find out more on it. The issue also covers topics to interest such as “Top 10 biotech spenders”, “Budget review 2015”, “Increasing support for GM crops and much more” . Also read interview coverage of Mr. Neeraj Kathuria, Chief Manager, IKP – BIRAC Regional Innovation Centre and Ms. Maggie Massam, Head, Business development, Clinical Practice Research, Data Link, UK at BioAsia 2015. Grab your copy now!

Budget 2015, new government and newer hopes. As a new financial year is all set to begin, the budget is looked upon with expectations from all spectrums. Amidst a plethora of hopes, would the biotech sector, which is on its way of embarking a new zenith, receive equal attention as others? Covering thoughts and expectations from various industry patrons on the same, we have carved out our cover story as “Budget 2015: Would the country’s CFO endorse Biotech sector?” The other stories to interest our readers are the updates and interviews from the likes of Mr.Jupally Krishna Rao, Minister of Industries and Commerce, Telangana, Dr. Mak Jawadekar, former R&D Director, Pfizer, Dr. CSN Murthy, CEO, Aurigene, Founder of start-up, eKincare from BioAsia 2015 held in February, “Top 7 Indian serial entrepreneurs”, a contribution by Novozyme “Re-think tomorrow with fuel from wastes” and much more. Grab the copy now and stay updated with the leading magazine of bioscience sector.

With Modi taking over the helm of the country, a string of hopes came attached with it. And with expectations flowing in for improvement in all the sectors, dearth in biotechnology sector remains the most awaited one to be addressed. Will the change in strategies and policies bring about the desired change in the sector? Will ‘Modi’nomic strategies be able to modify biotech sector? Read along with the February issue of Biotecnika magazine to have a look on the same. Various other latest happening of the bioscience world are covered under the headings “Ebola Outrage, is a cure round the corner?”, “Could artificial womb bring the next big technological revolution?”, a write-up by Novozymes on their Bioagricultural aspect and much more. The issue would have been incomplete without the precious support extended by Mr. Ramesh Swaminthan, CFO, Lupin. So, wait no more and grab your copy to stay updated with the latest industry trends.

With New Year comes new hope and expectations to upbeat the last year achievements and set newer targets for the days ahead. The one sector where the professionals strive for a hopeful future is Indian Biotech Industry. Infamously famous for unsatisfactory growth and peanut salaries, we wish this year brings a bunch of reasons to celebrate. Carving our cover story around the salary structure of a biotech professional this New Year, the issue offers a story on “Salary Special” and covers every element to decide “Who pays you the best in Biotech sector”. To further keep the interest intact, we have penned down articles from various verticals of bioscience domain such as “M&A- hurting or helping the industry”, “Google enters sequencing space”, “Will Modi’s Make in India change the fate of GM crops” and much more. The issue would have been incomplete without the gracious support from Dr. Anand, CEO, Bugworks and Titan Biotech who helped us to have an insight into the biotech industry and rest the curiosity of readers at peace. Grab your copy this New Year to get a fresh insight on biotech sector!

When the world is unassertive of advocating the usage of gene modifying technology, the world’s most populous country has stepped its foot forward in promoting GM food through all forms of media. While most of the developed countries still avert the usage of GMO’s, the step taken by China is quite commendable. This issue we have weaved our cover story around the same talking about “GM crops-Promotion vs. Relegation”. To interest our readers further, the issue also features “Eating Chicken or Antibiotics”, “GM labeling- is it our right to know?”, “Google further leaps into bioresearch” and much more. We would like to mention special thanks to Dr. Surinder Kher, CEO, Ecron Acunova and Mr. Jhenkar Dixit, CEO, GridOctane for their time and support. The issue also features Proteomics Lab inauguration by Thermo Fisher Scientific in the BT capital of India. Don’t let the best from bioscience sector go amiss. Grab your copy now!

With newer government came newer policies and hence newer hopes. One among those is the recent 'Make in India' initiative by Modi government. Emphasizing on attracting investors and hence improving job opportunity, it raises hope on dealing the lacuna that biotech sector faces, particularly the dearth in investments. The current issue of Biotecnika magazine analyses if Make in India would prove to be a stylish attempt to attract investments to BT sector? The other features to interest readers are 'Imminent second green revolution', 'CO2 to plastics- GE microbes answering global pollution', 'Delaying aging- an answer to delaying diseases?' and many more. Also see the feature covering Titan Biotech and Siro Clinfarm. With  much more to acquaint yourself with, wait no more and grab your copy now!

Biotecnika Magazine celebrates its first anniversary! In this festive season, as we celebrate our successful one year, catering to thousands of readers from bio community, we hope to improve upon the best further as well! We express our gratitude to our readers and mentors for all their appreciation and support. The cover feature of October issue details on how IT majors have been backing biotech industry and proving to be a ray of hope for biotech sector. With Google, SAP, Infosys and more IT giants extending their funding and support to biotechnology, the future of the industry definitely stands at a better place. An opportunity to interact with Novozyme Regional President, GS Krishnan; Dr. Jagadish Mittur from KBITS and New Horizon Group of Institutions and include excerpts from respective interviews, has been a valuable addition. To further interest the readers, the issue offers articles titled; “The battle to be BT capital,” “Recalling the exemption in service tax” and “Is the road to cancer heading nowhere?” Much more awaits! Grab your Anniversary Special Copy and Stay Updated!

When the wrath of deadly Ebola is showing its heinous side by causing a global pandemic and silently taking a toll on population across West African countries, finding a full stop to this problem is what scientists all across the globe are striving for. Biotechnology which has been the answer to many such unforeseen hurdles in the past is being looked upon with high expectations and why not! It has the potential to sway away many major problems. Biotecnika's September issue talks about the same and chalks out, 'If biotech biggies would churn out a remedy soon?' Other topics to interest our readers are 'The battle with HIV--when will we win?', Ban on GMO trials...where is the road taking us?' and much more..The issue also interacted with biotech big names such as Biocon Academy, Stempeutics and Sigma Aldrich to know the industry better. Wait no more and grab your copy of Biotecnika magazine now!

While transitions are utmost necessity of life, is biotech sector witnessing transition at a same pace? Are the expectations from bio-community near fulfillment? Though the roadmap to a perfect biotech culture is far away, the budget allocation for biotech does keep our hopes intact. Featuring the same, the cover story of this issue details on how the budget allocation has been received by the bio community and analyzes ‘Did Modi’s budget quench the thirst of BT sector?’ Other topics to interest our readers are ‘The bionic brain-boon to paralyses’, ‘Genetic identity- to be kept under wraps or unconcealed?’, ‘Bio fortified food’ and so on. That’s not all as the readers get to know industry giants Mr.V.S Reddy, MD, British Biologicals, Ms.Shobha V., Coonexios Life Sciences and Mrs. Mirella Marlow, Programme  Director, NICE, UK.  Wait no more and grab your copy of Biotecnika magazine now!

Academia, believed to be the backbone of a successful career, holds to be a pertinent fit for a bloom in biotech sector. A recipe of perfect mix between the subjective and practical knowledge, biotechnology demands nothing short of a \'perfectly\' equipped manpower for it\'s labs. But are Indian universities on the right track to make such impeccable biotech professionals? July issue covers the complete analysis of \'Is Biotech Academia Going the Right Way? to know what are the pluses and minuses of these universities. Other topics to interest our readers are the very controversial subjects such as \'Contemplating 3 Parent baby Procedure\', \'Futuristic Biotechnology-Fear or Favor?\' etc. It also brings the industry close by interviewing the ingenious personalities from Waters, Thermo Fisher Scientific, GVK and Manipal University. So what are you waiting for? Hop on to grab your copy of Biotecnika magazine to get a complete insight into the biotech world...

Media hypes that can make even the most insignificant junk of a story to a national issue has all the powers to help people form their opinions. Biotechnology being the most controversial yet a significant subjects on the timeline, needs media to be a cupid connecting the masses with science. But is the media obligating towards all the positive aspects? The June issue of Biotecnika magazine covers the different moods of media towards biotechnology under the title \'Is biotech industry facing media bias..? Who do we believe!?\' Retaining the soaring temperature of interests, the issue has \'Patents on seeds and GMOs..Resist or recognize their way into agriculture?\', \'Pfizer & AstraZeneca ..Duo dancing a mega deal\' and \'Indian Intellectual policies..time to turn the corners?\' and much more..Also the interview of Dr. Shekhar Mande, Director, NCCS gives an insight into the bridge that connects industry to academia. Grab a copy of magazine right away to rejuvenate your biotech interests.

To pump up the election fever that India is inundated with, Biotecnika Magazine with this issue adds the biotechnological aspect to the much awaited and anticipated elections. With the parties contesting to win the seats, will it do any good to the blooming biotech and pharma field? Would the manifestos promising the growth, stand out this time? Analysing this and much more, the cover story has all the elements to indulge in for. What\'s more? The magazine offers the readers a look onto the war between Patenters and Infringers that has made a headline recently, the major move of Ranbaxy being bought by Sun Pharma, How Biotech can manage and salvage the waste and much more.. To retain the interests, interview of the Nobel Laureate Dr. Thomas Sudhoff,  Mitra Biotech\'s President and CEO and that of Biozeen\'s Executive Director does the needful... Grab your copy of the magazine to avail the best of biotech industry...

The intensifying eye of FDA on the Indian units of many pharmaceutical and biotech companies has raised many eyebrows on the issue striving to figure out who is correct and who is not. The current issue talks about the same,analyzing and viewing the point of views of both the parties. Apart from the intriguing cover, the issue also includes the wonders of biotechnology such as \'Bio printing\' which assures to be the biopromise of the future. To make the interest of the readers it coves various other aspects of biotech world such as \'Criticism vs Biotech progress\', \' Bioregulators..are you listeing?\' etc. To add the flavor to the coming elections, the views and ideas of political biggies on biotechnology has been potrayed in \'with election on edge..what politicians pledge\'? This and much more awaits you in the April issue of Biotecnika magazine.Wait no more and subscribe to Biotecnika Magazine now...

This issue highlights fiction with a flight of Bio-fantasy and Cover Story of Emerging Asia-all slated to make a history in biotech world.

December 2018

June 2016

May 2016

April 2016

March 2016

February 2016

January 2016

December 2015

November 2015

October 2015

September 2015

August 2015

July 2015

June 2015

May 2015

April 2015

The essential guide to all the news in biotechnology industry & Academia run by India's Most popular Biotechnology Portal www.biotecnika.org. BioTecNika has access to world’s most influential Biotech entrepreneurs, Businesses and institutions. The magazine showcases all this via exclusive features that are insightful, informative and presented with style. 

Distinguished by its indepth analysis and latest information, BioTecNika has been an indispensable part of life of Biotechies for over 8+ years. Our well-heeled readership shape opinions and trends in India and across the region. This affluent and influential group is almost impossible to reach - except through the pages of BioTecNika

1. You agree that the use of Magzter.com, the application and its services, are at solely at your own risk. Neither Magzter.com nor its associates nor employees nor third party content providers guarantee that the service will be completely uninterrupted or error-free or foolproof against miscreant activities. Nor do they warranty that you will get the exact results as expected or promised by the website or product.

11. THE SERVICE AND ALL PUBLICATIONS ARE PROVIDED ON AN 'AS IS' AND 'AS AVAILABLE' BASIS. MAGZTER, ITS AFFILIATES, SUPPLIERS, LICENSORS AND AGENTS EXPRESSLY DISCLAIM ALL WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT. WITHOUT LIMITING THE FOREGOING, NEITHER MAGZTER NOR ITS AFFILIATES, SUPPLIERS, LICENSORS OR AGENTS, MAKES ANY WARRANTY THAT (I) THE SERVICE WILL MEET YOUR REQUIREMENTS, (II) THE SERVICE WILL BE UNINTERRUPTED, TIMELY, SECURE, OR ERROR-FREE, (III) THE INFORMATION THAT MAY BE OBTAINED FROM THE USE OF THE SERVICE OR THAT MAY BE CONTAINED IN THE PUBLICATIONS WILL BE ACCURATE OR RELIABLE, OR (IV) THE QUALITY OF ANY PUBLICATIONS OR THE SERVICE WILL MEET YOUR EXPECTATIONS. YOU ARE SOLELY RESPONSIBLE FOR OBTAINING AND MAINTAINING RELIABLE INTERNET CONNECTIVITY AND YOUR DEVICE. MAGZTER IS NOT RESPONSIBLE FOR YOUR INABILITY TO DOWNLOAD CONTENT. ANY MATERIAL DOWNLOADED OR OTHERWISE OBTAINED THROUGH THE USE OF THE SERVICE IS DONE AT YOUR OWN DISCRETION AND RISK AND YOU WILL BE SOLELY RESPONSIBLE FOR ANY DAMAGE TO YOUR COMPUTER SYSTEM OR MOBILE DEVICE OR LOSS OF DATA THAT RESULTS FROM THE DOWNLOAD OF ANY SUCH MATERIAL. NO ADVICE OR INFORMATION, WHETHER ORAL OR WRITTEN, OBTAINED BY YOU FROM MAGZTER OR THROUGH OR FROM THE SERVICE SHALL CREATE ANY WARRANTY.

2. You will maintain and promptly update that information to keep it true, accurate, current and complete. You are responsible for maintaining the confidentiality of your account and password and for restricting access to your computer, and you agree to accept responsibility for all activities that occur under your account, including the selection and use of all content and services.

2.You will maintain and promptly update that information to keep it true, accurate, current and complete. You are responsible for maintaining the confidentiality of your account and password and for restricting access to your computer, and you agree to accept responsibility for all activities that occur under your account, including the selection and use of all content and services.

3. In no event will Magzter.com or any person or entity or third party involved in the creation, production and distribution of the content on the website and the application be liable in contract or legally for any damages, including and not limited to, direct, indirect, incidental, special, and consequential incurred to you while or on using Magzter.com. By registering on the website or downloading the application, you agree that the provisions mentioned in this section shall apply to all use of and content on the website and the application.

3. Without prior written or authorised permission from Magzter, you should not modify, copy, distribute or sell any content obtained from Magzter as everything published here is the proprietary property of Magzter or its licensors. As such unauthorised use may also violate applicable laws including copyright and trademark laws, Magzter strictly prohibits these and will terminate your access and account if any such illegal activity is proved or detected. You should also stand liable for the damages caused by these unauthorised activities. Except as permitted by the Publication's lawful owner, you acknowledge that you do not acquire any ownership rights by downloading Publications accessed through the Service. Except as explicitly required under copyright law or permitted by the features of the Service you may not modify, reverse engineer, publish, transmit, display, participate in the transfer or sale, create derivative works of, or in any way commercially exploit or provide to a third party the content of the App, the Publications, or any portion of them without the express permission of Magzter and the owner of such content. We do not grant you any licenses, express or implied, to the intellectual property of Magzter or Magzter's licensors.

5. You specifically acknowledge that Magzter.com is not liable for any kind of defamatory or offensive or illegal conduct of other users or third parties or their content and that the risk of injury from the foregoing rests entirely with you.

8. Magzter reserves all rights to monitor the content published and inputted by you for the purpose of determining whether you are compliant with these terms and conditions and other operating rules determined by Magzter. Magzter has the right to take decisions about the content and delete them at its own will.

9. Magzter is a distributor and NOT a publisher of the Publications and so Magzter has no editorial control over the content, including opinions, advice, statements, services, offers etc., that is represented in the magazines. So Magzter will not take responsibility for the accuracy or the reliability for any information or facts provided therein or that is made available through the service, by anyone other than authorised Magzter employees who are acting on their official capacities. Accordingly, we have no editorial control over the Publications. Any opinions, advice, statements, services, offers or other information or content expressed or made available by third parties, including those made in Publications offered by the Service, are those of the respective author(s) or publisher(s) and not of Magzter. Magzter will not be liable for any loss or damage caused by your reliance on information obtained through the Service or from the Publications. The Service may contain links to other Internet sites and third-party resources and Magzter does not assume any responsibility or liability for communications or materials available at such linked sites. These links are provided for your convenience only. You are solely responsible for understanding any terms and conditions that may apply when you visit or place an order through a third-party site.

Details of the objectionable content, including its link on our platform

Download your favorite titles and read them offline, anytime and anywhere

Gift your loved ones with a Magzter Gift Card instantly and give them the freedom to read their favorite magazines and newspapers from thousands of best-selling titles.

Gift your loved ones with a Magzter Gift Card instantly and give them the freedom to read their favorite magazines from thousands of best-selling titles.

Gift your loved ones with a Magzter Gift Card instantly and give them the freedom to read their favorite magazines from {{magCount}} best-selling international titles.

Girish Ramdas is the Co-founder and CEO of Magzter, a New York based startup that has been making waves in the global digital publishing business. Magzter has crossed 80 million users since its inception in 2011 from more than 150+ countries with 1000s of magazines, newspapers and books from more than 4,500 publishers worldwide. He has more than 25 years of experience in cross-platform publishing, including print, mobile, and Web development. During this period, he has co-founded and run three successful start-up businesses. He has enabled magazine companies to go digital and helps them monetize their content across the digital world. Girish's deep industry experience in online, mobile and publishing ecosystems has made him an expert in acquisition, marketing and monetizing digital content across platforms globally.

In the event that you encounter any objectionable content on our platform, we have put in place a grievance redressal policy to address your concerns.

Magzter Inc. (“Company”, “we”, “us” or “our”) knows that you care about how your personal information is used and shared. Please read the following privacy policy (the “Policy”) to learn more about our privacy practices. By visiting any of the websites operated by the Company, and any sub-domains thereof, or using any of our mobile applications and other methods of content distribution (collectively, the “Service”), you acknowledge that you accept the practices and policies outlined in this Policy, and you hereby consent that we will collect, use, and share your information in the following ways.

Magzter Inc. is the World's largest and fastest growing self-service, cross-platform digital newsstand with over 80 million users since its inception in 2011 and thousands of magazines and newspapers across 40+ categories and 60+ languages. Headquartered in New York, Magzter has its local presence in Amsterdam, London, Mexico City, Chennai, Mumbai, New Delhi, Bengaluru, Singapore, and will soon be expanding to other countries. Founded by global entrepreneurs, Girish Ramdas and Vijay Radhakrishnan in June 2011, Magzter enables magazine and newspaper publishers around the world to create and deliver digital editions of their titles to global consumers.

Magzter is committed to providing a safe and secure platform for our users. Please note that Magzter is merely a platform for publishers to distribute their content. We do not control or endorse the content published on our platform. We cannot be held responsible for the actions of our publishers or their content.

Magzter is not responsible for compensating any party that has suffered damages or incurred costs due to any content, or part of the content, that violates their rights. Magzter is not liable to face any legal action in civil court for any violation of rights caused by any content, or part of the content, that infringes the rights of a third party.

Magzter offers the world’s largest {{allyoucanread}} subscription service called {{gold}} which gives digital readers unlimited access to 8,500+ magazines and newspapers for a monthly subscription price. Magzter also has the largest number of stories in the world with its game-changing ezRead 2.0 feature for its apps, which enables smartphone and small-screen mobile users to enjoy magazine content the way it was meant to be enjoyed, with article text that is easy to read and is accompanied by stunning videos and high resolution photography.

Magzter offers the world’s largest “All-You-Can-Read” subscription service called Magzter GOLD which gives digital readers unlimited access to 8,500+ magazines and newspapers for a monthly subscription price. Magzter also has the largest number of stories in the world with its game-changing ezRead 2.0 feature for its apps, which enables smartphone and small-screen mobile users to enjoy magazine content the way it was meant to be enjoyed, with article text that is easy to read and is accompanied by stunning videos and high resolution photography.

Name

Note: This will only share the cover and the publication information, but not the content.

Please fill out this form if you need any help regarding publishing your content on Magzter

Prior to Magzter, he was the President of Dot Com Infoway (DCI) and Galatta Media. His duties included strategic marketing, partnership development, and monetizing content globally. DCI grew from a small team of 3 in 2000 to 300 by 2011 and was dealing with web, software and app development for clients globally.

Since we launched, Magzter has been committed to partnering with global organizations to provide the greatest possible newsstand technology & service to our customers. Whether you are looking to offer magazine subscriptions to your customer database or just want to learn more, Magzter is committed to helping your business grow. To find out more, please fill out the questionnaire below:

The DMCA allows us to restore the removed content if the party filing the original DMCA Notice does not file a court action against you within ten business days of receiving the copy of your Counter Notice.

This Policy covers Company’s treatment of personally identifiable information (“Personal Information”) and other information about you and your computer or device that Company gathers when you are accessing the Service. We may collect Personal Information from you, as explained in more detail below, and we use this Personal Information internally in connection with our Services, including to personalize, provide, and improve our products, services, content, and advertising, and to allow you to set up a user account and profile, to contact you, to fulfill your requests for certain products and services, and to analyze how you use the Services. In certain cases, we may also share some Personal Information with third parties, but only as described in point 4.

This title is included with your Magzter GOLD subscription

To analyze the quality of content and provide appropriate feedback to publishers

We have designated a Grievance Officer to address any complaints related to objectionable content.

We request that any complaint related to objectionable content be sent to the Grievance Officer through email to the above-mentioned email address. We also request that you provide the following details when making a complaint:

and the App that provides you the capability to order, subscribe to and receive the delivery of various magazines, books, news and magazine and publication related content (collectively known as 'Publications') and to have these digital versions of the Publications delivered to you

c. We also collect information associated with your use of the application in order to make personalized recommendations. If you provide your third-party account credentials to us, you understand some content and/or information in those accounts (“Third Party Account Information”) may be transmitted into your account with us if you authorize such transmissions, and that Third Party Account Information transmitted to the Service is covered by this Policy.

f. The Personal Information we collect allows us to respond to your requests, improve our products and services, customize the advertising and content you see, and communicate with you about new products.

is the World's largest and fastest growing self-service, cross-platform digital newsstand with over 87 million users since its inception in 2011 and thousands of magazines and newspapers across 40+ categories and 60+ languages. Headquartered in New York, Magzter has its local presence in Amsterdam, London, Mexico City, Chennai, Mumbai, New Delhi, Bengaluru, Singapore, and will soon be expanding to other countries. Founded by global entrepreneurs, Girish Ramdas and Vijay Radhakrishnan in June 2011, Magzter enables magazine and newspaper publishers around the world to create and deliver digital editions of their titles to global consumers.

n. We will also use usage information in order to ensure users adhere to our Terms of Use. For example, a user’s usage information will help us confirm that a user only downloads a magazine or other content a permitted number of times or to a permitted number of devices.

which gives digital readers unlimited access to 8,500+ magazines and newspapers for a monthly subscription price. Magzter also has the largest number of stories in the world with its game-changing ezRead 2.0 feature for its apps, which enables smartphone and small-screen mobile users to enjoy magazine content the way it was meant to be enjoyed, with article text that is easy to read and is accompanied by stunning videos and high resolution photography.

{{magzter}} is the World's largest and fastest growing self-service, cross-platform digital newsstand with over 87 million users since its inception in 2011 and thousands of magazines and newspapers across 40+ categories and 60+ languages. Headquartered in New York, Magzter has its local presence in Amsterdam, London, Mexico City, Chennai, Mumbai, New Delhi, Bengaluru, Singapore, and will soon be expanding to other countries. Founded by global entrepreneurs, Girish Ramdas and Vijay Radhakrishnan in June 2011, Magzter enables magazine and newspaper publishers around the world to create and deliver digital editions of their titles to global consumers.

BioTecNika Magazine - March 2014

BioTecNika Magazine - March 2014

In this issue

BioTecNika Magazine Description: